Clinical and functional determinants of motor reserve in patients with de novo Parkinson’s disease
Objective: To determine the clinical determinants and the role of serotonergic innervation on motor reserve in patients with de novo Parkinson's disease. Background: Patients with…The hypometabolism in anterior cingulate gyrus and thalamus: potential biomarkers of disease progression in progressive supranuclear palsy
Objective: This study aimed to identify differences in FDG uptake and metabolic covariant network (independent component analysis) in progressive supranuclear palsy (PSP) in comparison with…Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration
Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra…Clinical and radiological gender differences in Parkinson’s disease
Objective: To assess clinical and brain metabolic gender differences in a cohort of patients with PD Background: Many studies have elucidated gender-related clinical differences in…The impact of STN-DBS on brain metabolic activity during dynamic obstacle avoidance in Parkinson’s disease
Objective: To describe brain metabolic activity changes during dynamic obstacle avoidance in parkinsonian patients with subthalamic deep brain stimulation (STN-DBS) Background: STN-DBS does not offer…A network imaging biomarker of X-linked dystonia-parkinsonism
Objective: To characterize a metabolic brain network associated with X-linked dystonia-parkinsonism (XDP). Background: X-linked dystonia-parkinsonism (XDP, DYT/PARK-TAF1, Lubag) is an X-linked recessive movement disorder characterized…Non-tremor motor dysfunction in Parkinson’s disease is associated with decreased [18F]FMPEP-d2 binding
Objective: To explore the relationship between cannabinoid receptor type 1 (CB1) availability and motor symptoms in Parkinson’s disease (PD) with [18F]FMPEP-d2 positron emission tomography (PET).…An in-vivo study of regional synaptic density loss in patients with Multiple System Atrophy using [11C]UCB-J PET molecular imaging.
Objective: We present preliminary, cross-sectional data, on the in-vivo evaluation of pre-synaptic terminal density in the brain of patients with Multiple System Atrophy (MSA) compared…Multimodal neuroimaging of Parkinson’s disease with diffusion tensor imaging (DTI) and dopamine transporter (DAT) positron emission tomography
Objective: The main aims of this study were to characterize brain microstructure alterations in a cross-sectional cohort of Parkinson’s disease (PD) with DTI and assess…Early-phase 18F-FP-CIT PET images: a promising imaging biomarker for predicting early dementia conversion in Parkinson’s disease
Objective: This study aims to investigate whether early-phase 18F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) positron emission tomography (PET) images (i.e., images acquired within the first 10 min after…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 33
- Next Page »